Morphosys this week presented its new antibody technology Ylanthia, the next generation of the company’s HuCAL platform.
According to the company, Ylanthia is the industry’s largest fragment antigen binding library, comprising more than 100 billion distinct human antibodies, with all antibodies pre-selected for expression levels, stability, and aggregation behavior. The company optimizes the Ylanthia library with its Slonomics technology, which, it said, offers improved speed and flexibility compared to its HuCAL line.
Gentel this week launched its new Colony Surveillance Assays for monitoring specific pathogen-free status in nonhuman primates.
The panel uses Gentel’s Proteomics Multi-System and tests for 11 infectious agents including rhesus rhadinovirus and spumavirus simian foamy virus.